Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023.
To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist and editorial board member, Dr. Ken Kato (National Cancer Centre Hospital, Tokyo, Japan).
Associated abstracts:
Shitara K, et al. Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: the phase 3 KEYNOTE-585 study. ESMO Congress 2023, LBA74
Janjigian YY, et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase 3 MATTERHORN study. ESMO Congress 2023, LBA73
Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase 3, randomized, double-blind, placebo-controlled KEYNOTE-811 study. ESMO Congress 2023, Abstract 1511O
Van der Wilk BJ, et al. Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial. ESMO Congress 2023, LBA75
Disclosures: Ken Kato has received grant/research support from ONO and BMS; acted on the advisory board for ONO, BMS, Chugai, Daiichi Sankyo and AstraZeneca; and been a speaker’s bureau participant with ONO, BMS and MSD.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of the ESMO 2023
Click here for more content on gastrointestinal cancer & for further ESMO 2023 highlights visit here.
